Jolanda van Hal November in review: GLP-1 breakthroughs, UPFs under fire, Novonesis advances healthy longevity Jolanda van Hal Key takeaways GLP-1 science, product pipelines, and consumer acceptance reached a pivotal point in November, reshaping nutrition, pharma, and metabolic health
[DOI] [PubMed] [Google Scholar] Scherz-Shouval R, Elazar Z
[DOI] [PubMed] [Google Scholar] 42.Sikiric P., Seiwerth S., Rucman R., Turkovic B., Rokotov D.S., Brcic L., Sever M., Klicek R., Radic B., Drmic D., et al
Nie jest rwnie przeznaczony dla kobiet w ciy, karmicych piersi ani z cik niewydolnoci nerek
Patients who had been on monotherapy for at least 6 months and on combination therapy for at least 12 months were registered in the study
& Rogers, J